Filtered Listing Testing
Free Educational Program Will Offer Expert Insight On Age-Related Macular Degeneration Condition
Three world-renowned vision scientists received The Helen Keller Prize for Vision Research, which honors scientific discovery and excellence.
BrightFocus Foundation, an international nonprofit funder of Alzheimer’s, macular degeneration, and glaucoma research, presented its named vision awards for 2022 yesterday to leading vision researchers at the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO).
BrightFocus-funded researchers—assisted by a citizen science video game-- were among the first to show that Alzheimer’s contributes to stalls in the brain’s tiniest blood vessels, and they’re working on possible treatments.
BrightFocus Foundation Awards Nearly $24 Million in New Research for Alzheimer’s and Vision Diseases
Global Nonprofit’s Science Support Leads to Breakthroughs
Scientists have discovered that a rare version of the so-called “neutral” APOE3 genotype, one they’ve named APOE3-Jacksonville (APOE3-Jac), may help protect against Alzheimer’s through increased lipid binding and cholesterol removal.
Years ago, a BrightFocus grantee said it might be possible to manipulate the blood-brain-barrier to treat Alzheimer’s disease. Now his hypothesis is driving an international effort to develop drugs for this purpose.
New evidence shows the same molecular pathway contributes to inflammation in AMD and lupus, helping to drive a hyperactive immune response in both diseases. The discovery could fast-track development and approval of existing anti inflammatory drugs to treat AMD.
Why does the impact of an Alzheimer’s risk factor vary by race and genetic ancestry? Researchers are learning the answers.